• SPX
  • $5,712.69
  • -0.28 %
  • -$16.11
  • DJI
  • $41,824.32
  • 0.07 %
  • $29.72
  • N225
  • $38,474.90
  • 1.11 %
  • $421.23
  • FTSE
  • $8,166.43
  • -0.22 %
  • -$17.81
  • IXIC
  • $18,285.78
  • 0.58 %
  • $105.79
Prometheus Biosciences, Inc. (RXDX) Stock Price, News & Analysis

Prometheus Biosciences, Inc. (RXDX) Stock Price, News & Analysis

Currency in USD Disclaimer

NA

NA

NA

Day's range
$199.92
Day's range
$199.96
50-day range
$106.405
Day's range
$199.98
  • Country: US
  • ISIN: US74349U1088
52 wk range
$23.27
Day's range
$199.96
Notice: This company has been marked as potentially delisted and may not be actively trading.


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 94.06
  • Piotroski Score 2.00
  • Grade Perform
  • Symbol (RXDX)
  • Company Prometheus Biosciences, Inc.
  • Price $199.92
  • Changes Percentage (0.09%)
  • Change $0.18
  • Day Low $199.92
  • Day High $199.96
  • Year High $199.96

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 05/13/2021
  • Fiscal Year End N/A

  • Average Stock Price Target $142.00
  • High Stock Price Target $200.00
  • Low Stock Price Target $67.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$3.54
  • Trailing P/E Ratio -56.474576271186
  • Forward P/E Ratio -56.474576271186
  • P/E Growth -56.474576271186
  • Net Income $-141,752,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.